AI Article Synopsis

  • Atypical antipsychotics (AAPs) can help reduce delirium duration in ICUs, but their long-term use poses serious risks, particularly increased mortality in the elderly.
  • A study revealed that 55% of ICU patients prescribed AAPs continued their use after discharge, with male patients and those discharged to a healthcare facility being more likely to persist with the medication.
  • The findings suggest a need for strategies to address the inappropriate continuation of AAPs after hospital discharge to minimize long-term health risks.

Article Abstract

Background: Atypical antipsychotics (AAP) have been associated with reduced duration of delirium in the intensive care setting. However, long-term use of these drugs is associated with significant adverse events, including increased all-cause mortality in the elderly. Inappropriate continuation of AAPs after discharge from the intensive care unit (ICU) is worrisome and needs to be addressed.The aim of this work was to assess the prevalence of continuation of AAPs after hospital discharge and evaluate the associated risk factors.

Method: This was a single-center retrospective chart analysis in the setting of adult ICUs at a tertiary care academic medical center. It involved all adult patients admitted to the ICU and initiated on AAPs from January 2012 to December 2014. The measurements were: (1) prevalence of ICU-initiated AAP continuation following hospital discharge, (2) risk factors associated with continuation of AAPs following hospital discharge, and (3) risk of continuation of AAPs in patients ⩾65 years of age.

Results: A total of 55% of ICU patients initiated on AAPs were discharged from the hospital with a prescription for continued AAP therapy. Male sex and discharge location were highly associated with continuation upon discharge. Older patients (⩾65 years of age) were not at a higher risk of being continued on these drugs after discharge.

Conclusion: Male sex and discharge to a healthcare facility were associated with a higher rate of continuation. Research into practical methods to reduce their continuation upon discharge should be performed to mitigate the long-term risks of AAP administration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463330PMC
http://dx.doi.org/10.1177/2042098618809933DOI Listing

Publication Analysis

Top Keywords

continuation aaps
16
hospital discharge
12
continuation
9
discharged hospital
8
single-center retrospective
8
intensive care
8
discharge
8
aaps hospital
8
initiated aaps
8
discharge risk
8

Similar Publications

Formulation, Development, and Characterization of AMB-Based Subcutaneous Implants using PCL and PLGA via Hot-Melt Extrusion.

AAPS PharmSciTech

December 2024

Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Mississippi, 38677, USA.

The hot-melt extrusion process is currently considered a prominent manufacturing technique in the pharmaceutical industry. The present study is intended to develop amlodipine besylate (AMB)-loaded subcutaneous implants to reduce the frequency of administration, thus improving patient compliance during hypertension management. AMB subcutaneous implants were prepared using continuous hot-melt extrusion technology using poly(caprolactone) and poly(lactic-co-glycolic acid) with dimensions of 3.

View Article and Find Full Text PDF

Interference of Plasticizers on Plasma Protein Binding Measurements.

AAPS J

December 2024

Pfizer Worldwide Research and Development, Groton, CT, USA.

Accurate measurement of plasma protein binding (PPB) is of critical importance in drug discovery. Methodologies for PPB measurement continue to evolve to address the challenges of highly bound compounds. In order to generate high quality PPB data, it is crucial to not only apply state-of-the-art methods and highly sensitive and selective detectors, but also use high-quality plasma.

View Article and Find Full Text PDF

Background: Open-source automated insulin delivery systems are increasingly adopted yet predominantly discussed outside of Asia. This study aimed to describe efficacy and safety of android artificial pancreas (AAPS) in people with type 1 diabetes mellitus (T1DM) from mainland China.

Methods: This real-world study recruited people who initiated AAPS for ≥ 3 months between 2019 and 2024.

View Article and Find Full Text PDF

Remote Regulatory Assessments of Bioavailability/Bioequivalence Study Conduct by the Office of Study Integrity and Surveillance.

AAPS PharmSciTech

October 2024

Office of Study Integrity and Surveillance, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, United States Department of Health and Human Services, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993-0002, USA.

The Office of Study Integrity and Surveillance (OSIS) in CDER in FDA coordinates and conducts inspections of sites conducting bioavailability and/or bioequivalence (BA/BE) studies supporting regulatory submissions. In response to travel restrictions during the SARS-CoV-2 (COVID-19) public health emergency, OSIS developed and began conducting remote assessments of BA/BE sites in 2020. This paper provides an overview of remote regulatory assessments (RRAs) and OSIS's approach to RRAs, including procedures, experiences, and examples of findings during RRAs.

View Article and Find Full Text PDF

Background: Recent studies have shown that liver enzyme abnormalities were not only seen with typical antipsychotics (APs) but also with atypical antipsychotics (AAPs). During the last 20 years, the hepatotoxicity of various antipsychotics received much attention. However, systematic evaluations of hepatotoxicity associated with APs are limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!